ClinicalTrials.gg
Active, not recruitingNCT02725060Updated Nov 10, 2026

Autoimmune Basis for Postural Tachycardia Syndrome

An interventional study of phenylephrine and isoproterenol in Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome and Tachycardia, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Other

How we know

Updated Nov 10, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center — 2 open to participants now, 13 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · Vanderbilt University Medical Center.

Planned enrollment
2nd of 13
58 · median 40
Started
2016
the only one that year
No phase
5 of 18
none open now
Primary completion
2027-02
later than 7 of 12 live
Registered
7th of 18
by date

Among the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2016, is one of 5 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 7th registered.

Postural Orthostatic Tachycardia Syndrome

136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.

Browse Postural Orthostatic Tachycardia Syndrome studies →

Open to participants now

2 of the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

The purpose of this study is to see if some people with postural tachycardia syndrome (POTS) have higher levels of immune proteins (autoantibodies) directed against receptors of the autonomic nervous system, and if these autoantibodies make a difference in their POTS symptoms. The investigators also want to see if the levels of these autoantibodies stay the same over time.

Read the detailed description

Postural tachycardia syndrome (POTS) is a debilitating disorder resulting from cardiovascular autonomic dysfunction, has many causes and is very difficult to treat effectively. The investigators have identified the presence of autoantibodies (immune proteins) directed against some receptors of the autonomic nervous system that can cause patient's symptoms on standing.

The present study is designed to test the hypothesis that patients with POTS harbor functional autoantibodies to adrenergic receptors that lead to an excessive tachycardia characteristic of POTS. For this purpose, this study will define the prevalence, burden, and the in vivo physiological significance of these adrenergic antibodies in a well-phenotyped and representative cohort of patients with POTS and a matched cohort of healthy control subjects, and will characterize the stability of these autoantibodies over time in affected POTS patients.

03

Conditions studied

  • Postural Orthostatic Tachycardia Syndrome
  • Postural Tachycardia Syndrome
  • Tachycardia
  • Arrhythmias, Cardiac
  • Autonomic Nervous System Diseases
  • Orthostatic Intolerance
  • Cardiovascular Diseases
  • Primary Dysautonomias

Keywords

  • POTS
  • Orthostatic Intolerance
  • Orthostatic Tachycardia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-50 years old
  • Postural Tachycardia Syndrome: Heart rate increase >30 bpm from supine within 10 min of standing, in the absence of orthostatic hypotension (>20/10 mmHg fall in blood pressure), with chronic symptoms (> 6 months), and in the absence of other acute cause of orthostatic tachycardia.
  • Able and willing to provide
  • Female premenopausal subjects must utilize adequate and willingness to undergo serum beta-hCG testing
  • The subject must understand and be able to comply with the study procedures and restrictions.

Exclusion criteria

Exclusion Criteria:

  • Hypertension (>150 mmHg systolic and >100 mmHg diastolic) based on history or findings at screening.
  • Orthostatic hypotension (consistent drop in blood pressure >20/10 mmHg with 10 min stand)
  • Pregnancy
  • Cardiovascular disease, such as myocardial infarction within 6 months, angina pectoris, significant arrhythmia (sinus tachycardia is not excluded), deep vein thrombosis, pulmonary embolism
  • History of serious neurologic disease
  • History or presence of significant immunological or hematological disorders
  • gastrointestinal impairment that could interfere with dietary compliance or drug absorption
  • Impaired hepatic function ( and/or alanine amino transaminase >1.5 x )
  • Impaired renal function (serum creatinine >1.5 mg/dL)
  • Hematocrit \<28%
  • Current or concurrent disease that could affect the absorption, action or disposition of the drug, or clinical or laboratory assessments.
  • Any underlying or acute disease requiring regular medication that could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult
  • Inability to comply with the protocol

Healthy control subjects will be healthy, non-smoking and on no chronic medications at the time of the study. Healthy control subjects will be group-matched to the POTS patients for age and gender. We will attempt to study female patients in the first half of their menstrual cycle to minimize cyclical variability.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Autonomic and Antibody Assessments

    On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case: * Posture study with blood samples for autoantibody testing * 24-hour heart rhythm and blood pressure monitoring * autonomic function tests * Quantitative Axonal Sudomotor Reflex Testing * Total blood volume assessment * Pharmacologic testing with phenylephrine * Pharmacologic testing with isoproterenol * Cardiac output with rebreathing * Assessment of splanchnic capacitance * Microneurography

    Drug: phenylephrine · Drug: isoproterenol · Radiation: 25 micro-Ci of radiation · Procedure: Posture study with blood samples · Procedure: 24-hour heart rhythm and blood pressure monitoring · Procedure: Quantitative Axonal Sudomotor Reflex Testing · Procedure: Autonomic function tests · Other: Rebreathing test · Other: Assessment of splanchnic capacitance · Procedure: microneurography

Interventions

  • Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg

  • Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.

    Also known as: isuprel, isoprenaline

  • Radiation25 micro-Ci of radiation

    Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.

    Also known as: DAXOR

  • ProcedurePosture study with blood samples

    Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.

    Also known as: orthostatic challenge, orthostatic stress test

  • Procedure24-hour heart rhythm and blood pressure monitoring

    Blood pressure, heart rate and ECG monitoring for 24 hours

    Also known as: 24 Holter

  • ProcedureQuantitative Axonal Sudomotor Reflex Testing

    The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.

    Also known as: QSART, sweat test

  • ProcedureAutonomic function tests

    The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.

  • OtherRebreathing test

    Cardiac output will be measured using the rebreathing technique (Innocor)

    Also known as: cardiac output measurement

  • OtherAssessment of splanchnic capacitance

    Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves

  • Proceduremicroneurography

    microneurography will be measured in the peroneal nerve to assess sympathetic activity.

    Also known as: msna

06

What researchers measure

Primary outcomes

  1. Autoantibody levels

    Blood samples collected while supine during the posture study will be analyzed for autoantibody positivity in POTS patients and control subjects.

    Time frame: up to 10 minutes

  2. Blood pressure after phenylephrine boluses

    Time frame: 1-2 minutes after bolus injections

  3. Heart rate after isoproterenol boluses

    Time frame: 1-2 minutes after bolus injections

  4. Orthostatic change in heart rate

    Difference between standing and supine heart rates.

    Time frame: up to 10 minutes

Secondary outcomes

  1. Blood pressure response during phase IV of the Valsalva maneuver

    Time frame: up to 10 minutes

  2. Hear rate response during phase IV of the Valsalva maneuver

    Time frame: up to 10 minutes

07

Study locations

2 sites
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73117-1213, United States
  • Autonomic Dysfunction Center
    Nashville, Tennessee 37232, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2016 (actual). Primary completion is estimated for Feb 2027, 132 months after the start.

Of 44 non-industry interventional studies with no phase under Postural Orthostatic Tachycardia Syndrome, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 61. This study's planned 132 months is above that.

Counting every sponsor, half of 44 studies reached it within 46 months; a quarter within 20 and three quarters within 61.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Feb 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2016
First posted
Mar 31, 2016
StartActual
Feb 2016
Primary completionEst.
Feb 2027was Oct 2026
CompletionEst.
Jun 2027was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Nov 10, 2026
Primary completion
Oct 2026→Feb 2027
Nov 10, 2026
Study completion
Dec 2026→Jun 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Oct 2026→Feb 2027
    Study completion Dec 2026→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02725060
Responsible party
Luis E Okamoto (Research Instructor, Vanderbilt University Medical Center) — Principal investigator
First posted
Mar 31, 2016
Start date
Feb 2016
Primary completion
Feb 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Luis Okamoto, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Phenylephrine · Isoproterenol

Start the discussion